Bradley Campbell Sells 75,000 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD) CEO Bradley Campbell sold 75,000 shares of the company’s stock in a transaction dated Tuesday, January 20th. The shares were sold at an average price of $14.31, for a total transaction of $1,073,250.00. Following the completion of the transaction, the chief executive officer owned 1,021,180 shares in the company, valued at $14,613,085.80. This trade represents a 6.84% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Amicus Therapeutics Stock Performance

NASDAQ:FOLD opened at $14.28 on Friday. The stock has a fifty day moving average price of $12.23 and a 200-day moving average price of $9.27. The company has a market cap of $4.48 billion, a price-to-earnings ratio of -356.79 and a beta of 0.42. The company has a debt-to-equity ratio of 1.70, a quick ratio of 2.09 and a current ratio of 2.99. Amicus Therapeutics, Inc. has a fifty-two week low of $5.51 and a fifty-two week high of $14.38.

Amicus Therapeutics (NASDAQ:FOLD) last issued its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.17 EPS for the quarter, topping analysts’ consensus estimates of $0.12 by $0.05. The company had revenue of $169.06 million for the quarter, compared to analysts’ expectations of $165.24 million. Amicus Therapeutics had a positive return on equity of 6.95% and a negative net margin of 2.35%.Amicus Therapeutics’s revenue was up 19.5% on a year-over-year basis. During the same quarter last year, the business earned $0.10 earnings per share. As a group, equities analysts anticipate that Amicus Therapeutics, Inc. will post 0.15 EPS for the current fiscal year.

Hedge Funds Weigh In On Amicus Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in FOLD. Vestal Point Capital LP increased its stake in Amicus Therapeutics by 178.4% in the 2nd quarter. Vestal Point Capital LP now owns 11,900,000 shares of the biopharmaceutical company’s stock worth $68,187,000 after acquiring an additional 7,625,000 shares during the last quarter. Norges Bank purchased a new stake in shares of Amicus Therapeutics in the 2nd quarter valued at $18,540,000. Qube Research & Technologies Ltd grew its stake in shares of Amicus Therapeutics by 223.9% during the second quarter. Qube Research & Technologies Ltd now owns 3,466,911 shares of the biopharmaceutical company’s stock valued at $19,865,000 after buying an additional 2,396,410 shares during the last quarter. State Street Corp lifted its position in Amicus Therapeutics by 21.5% in the second quarter. State Street Corp now owns 11,568,097 shares of the biopharmaceutical company’s stock valued at $66,285,000 after purchasing an additional 2,049,078 shares during the last quarter. Finally, Iron Triangle Partners LP purchased a new position in shares of Amicus Therapeutics in the third quarter worth $15,534,000.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. The Goldman Sachs Group increased their price objective on shares of Amicus Therapeutics from $9.00 to $11.00 and gave the stock a “neutral” rating in a research report on Wednesday, November 5th. Leerink Partners downgraded shares of Amicus Therapeutics from an “outperform” rating to a “market perform” rating and lowered their price objective for the stock from $17.00 to $14.50 in a report on Monday, December 29th. Cantor Fitzgerald cut Amicus Therapeutics from an “overweight” rating to a “hold” rating and cut their target price for the company from $21.00 to $14.50 in a research report on Friday, December 19th. TD Cowen lowered shares of Amicus Therapeutics from a “buy” rating to a “hold” rating and set a $14.50 price objective for the company. in a research note on Monday, December 22nd. Finally, Guggenheim downgraded shares of Amicus Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, eight have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $15.55.

About Amicus Therapeutics

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.